|
Posaconazole has superior clinical efficacy and cost-effectiveness than itraconazole for
antifungal prophylaxis in allogeneic stem cell transplant recipients: A single-centre
experience (click for details) |
|
|
|
Allergic bronchopulmonary aspergillosis (click for details) |
|
|
|
Amphotericin B, voriconazole and caspofungin activity against Aspergillus fumigatus in
an in vitro pharmacokinetic/pharmacodynamic (PK/PD) diffusion system simulating
human pharmacokinetics (click for details) |
|
|
|
Characteristics of vulvovaginitis caused by Saccharomyces cerevisiae and antifungal
susceptibility of clinical isolates (click for details) |
|
|
|
Therapeutic drug monitoring of voriconazole in pediatric patients (click for details) |
|
|
|
FUNGISOME - a new liposomal amphotericin B preparation for treatment of invasive
fungal infections developed in India (click for details) |
|
|
|
Cumulative Diagnostic Value of Galactomannan and Anti-Aspergillus Antibodies
Detection in Children with Haematooncology Diseases (click for details) |
|
|
|
Comparison of the effects of deoxycholate amphotericin B and amphotericin B lipid
complex on the gene exression of inflammatory cytokines and receptors in human
monocytes exposed to Candida albicans (click for details) |
|
|
|
Building work in a paediatric haematology/oncology unit: successful strategies to
prevent invasive fungal infection in immunocompromised patients during construction
of HEPA-filtered cubicles (click for details) |
|
|
|
Susceptible patterns of Candida species isolates from a Portuguese oncology
population - changing strategies? (click for details) |
|
|
